Dupilumab for recalcitrant prurigo nodularis: Case report
Dupilumab is a recombinant fully human monoclonal antibody modulating the signaling of the interleukin (IL)-4 and IL-13 pathways and has been approved for the treatment of moderate/severe atopic dermatitis. We present a case of recalcitrant prurigo nodularis treated off-label with dupilumab.
Sábháilte in:
| Príomhchruthaitheoirí: | , , |
|---|---|
| Formáid: | LEABHAR |
| Foilsithe / Cruthaithe: |
Sociedade Portuguesa de Dermatologia e Venereologia,
2022-01-01T00:00:00Z.
|
| Ábhair: | |
| Rochtain ar líne: | Connect to this object online. |
| Clibeanna: |
Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|
Ar líne
Connect to this object online.3rd Floor Main Library
| Gairmuimhir: |
A1234.567 |
|---|---|
| Cóip 1 | Ar fáil |